Clinical Trial Update: Randomized, Crossover Safety and Pharmacokinetics Study of PT010 [Phase 1]

View source ↗

Summary

A Phase 1 randomized, crossover study assessed the safety and pharmacokinetics of PT010 in COPD and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT010

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: COPD | Phase 1 | Status: COMPLETED